HomeDenmarkTwelve New Companies Enter BioInnovation Institute's Venture Lab

Twelve New Companies Enter BioInnovation Institute’s Venture Lab

BioInnovation Institute

BioInnovation Institute, a Copenhagen, Denmark-based international non-profit foundation incubating and accelerating life science research, announced that twelve new companies have entered its Venture Lab acceleration program for early-stage companies.

The cohort is strategically aligned with BII’s focus on supporting innovative early-stage startups that can improve human and planetary health.

The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of EUR 500,000 (approximately 4M DKK) plus access to labs and offices at the BII in Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII’s Venture House program. 

Each start-up will be supported in undertaking the necessary steps to reach initial proof-of-concept, to make a business plan and to set up a team. The new ventures will be guided in developing a detailed milestone plan and will be assisted in overcoming the challenges of growing a business allowing them to progress rapidly towards the market.

The new companies BII has accepted into the Venture Lab acceleration program are:

Planetary Health

  • CAMBIOTICS is developing precision probiotics for PFAS detoxification.
  • SNL Biosolutions has developed an innovative technology platform that can produce fermentation-based oils at scale and prevent deforestation. The technology can be used to produce a wide range of products spanning from food ingredients to sustainable aviation fuel.
  • SymbioMATCH produces effective biofertilizers tailored to each soil condition and legume crop.


  • PreTT is a pioneer in advancing pre-targeted radioimmunotherapies to improve the lives of millions of cancer patients. 
  • Polyceutix is innovating cancer treatment by freeing the immune system exactly where it is needed. 

Women’s Health

  • Pharmista Technologies is developing a reusable pregnancy test which will be the start of a new generation of reusable diagnostics.
  • oasicare is on a mission to improve women’s health during childbirth and postpartum on a global scale. The company’s first solution is a medical device preventing the risk of birth tears. 

Health Tech

  • Zeta Diagnostics is developing a portable audio device that allows physicians to detect middle ear problems before they become permanent complications. 
  • Glaze Life Sciences is developing a non-invasive device to measure blood glucose to improve the everyday life of people living with diabetes.


  • DiaSense is developing a quantum diamond-magnetic microscope to be used by neuroscientists to diagnose diseases and find cures.
  • Sqale is innovating biomanufacturing by using quantum technologies.
  • Alea Quantum Technologies has developed a quantum random number generator that will enable safe and trusted data sharing in the post-quantum era.

Since its inception in 2018, BII has supported 100 startups and projects with €89m alongside the venture capital, industry and business expertise it provides to help them accelerate to the next level.  In total, BII’s startups have raised over €428m in external funding from both local and international investors. Recent company successes include Embark Laboratories, Adcendo, Stipe Therapeutics, Twelve Bio, Octarine Bio, and Cirqle Biomedical.